Tubular Acidification Defect in Adults with Sickle Cell Disease.


Journal

Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570

Informations de publication

Date de publication:
07 01 2020
Historique:
received: 08 07 2019
accepted: 29 10 2019
pubmed: 12 12 2019
medline: 1 6 2021
entrez: 12 12 2019
Statut: ppublish

Résumé

Metabolic acidosis is a frequent manifestation of sickle cell disease but the mechanisms and determinants of this disorder are unknown. Our aim was to characterize urinary acidification capacity in adults with sickle cell disease and to identify potential factors associated with decreased capacity to acidify urine. Among 25 adults with sickle cell disease and an eGFR of ≥60 ml/min per 1.73 m Of the participants (median [interquartile range] age of 36 [24-43] years old, 17 women), 12 had a normal and 13 had an abnormal response to the test. Among these 13 participants, nine had normal baseline plasma bicarbonate concentration. Plasma aldosterone was within the normal range for all 13 participants with an abnormal response, making the diagnosis of type 4 tubular acidosis unlikely. The participants with an abnormal response to the test were significantly older, more frequently treated with oral bicarbonate, had a higher plasma uric acid concentration, higher hemolysis activity, lower eGFR, lower baseline plasma bicarbonate concentration, higher urine pH, lower urine ammonium ion excretion, and lower fasting urine osmolality than those with a normal response. Considering both groups, the maximum urinary ammonium ion excretion was positively correlated with fasting urine osmolality ( Among adults with sickle cell disease, impaired urinary acidification capacity attributable to distal tubular dysfunction is common and associated with the severity of hyposthenuria. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_12_10_CJN07830719.mp3.

Sections du résumé

BACKGROUND AND OBJECTIVES
Metabolic acidosis is a frequent manifestation of sickle cell disease but the mechanisms and determinants of this disorder are unknown. Our aim was to characterize urinary acidification capacity in adults with sickle cell disease and to identify potential factors associated with decreased capacity to acidify urine.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
Among 25 adults with sickle cell disease and an eGFR of ≥60 ml/min per 1.73 m
RESULTS
Of the participants (median [interquartile range] age of 36 [24-43] years old, 17 women), 12 had a normal and 13 had an abnormal response to the test. Among these 13 participants, nine had normal baseline plasma bicarbonate concentration. Plasma aldosterone was within the normal range for all 13 participants with an abnormal response, making the diagnosis of type 4 tubular acidosis unlikely. The participants with an abnormal response to the test were significantly older, more frequently treated with oral bicarbonate, had a higher plasma uric acid concentration, higher hemolysis activity, lower eGFR, lower baseline plasma bicarbonate concentration, higher urine pH, lower urine ammonium ion excretion, and lower fasting urine osmolality than those with a normal response. Considering both groups, the maximum urinary ammonium ion excretion was positively correlated with fasting urine osmolality (
CONCLUSIONS
Among adults with sickle cell disease, impaired urinary acidification capacity attributable to distal tubular dysfunction is common and associated with the severity of hyposthenuria.
PODCAST
This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_12_10_CJN07830719.mp3.

Identifiants

pubmed: 31822527
pii: 01277230-202001000-00007
doi: 10.2215/CJN.07830719
pmc: PMC6946065
doi:

Substances chimiques

Ammonium Compounds 0
Sodium Potassium Chloride Symporter Inhibitors 0
Furosemide 7LXU5N7ZO5
Fludrocortisone U0476M545B

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-24

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Références

Scheinman JI: Sickle cell disease and the kidney. Nat Clin Pract Nephrol 5: 78–88, 2009 19048000
Nath KA, Hebbel RP: Sickle cell disease: Renal manifestations and mechanisms. Nat Rev Nephrol 11: 161–171, 2015 25668001
Nath KA, Katusic ZS: Vasculature and kidney complications in sickle cell disease. J Am Soc Nephrol 23: 781–784, 2012 22440903
Sharpe CC, Thein SL: Sickle cell nephropathy - a practical approach. Br J Haematol 155: 287–297, 2011 21902687
Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B, Lai C, Rowe JH, Gowhari M, Hassan J, Desimone J, Machado RF, Gladwin MT, Little JA, Gordeuk VR: Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol 164: 729–739, 2014 24329963
Deux JF, Audard V, Brugières P, Habibi A, Manea E-M, Guillaud-Danis C, Godeau B, Galactéros F, Stehlé T, Lang P, Grimbert P, Audureau E, Rahmouni A, Bartolucci P: Magnetic resonance imaging assessment of kidney oxygenation and perfusion during sickle cell vaso-occlusive crises. Am J Kidney Dis 69: 51–59, 2017 27663041
Merle NS, Grunenwald A, Rajaratnam H, Gnemmi V, Frimat M, Figueres ML, Knockaert S, Bouzekri S, Charue D, Noe R, Robe-Rybkine T, Le-Hoang M, Brinkman N, Gentinetta T, Edler M, Petrillo S, Tolosano E, Miescher S, Le Jeune S, Houillier P, Chauvet S, Rabant M, Dimitrov JD, Fremeaux-Bacchi V, Blanc-Brude OP, Roumenina LT: Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight 3: 96910, 2018 29925688
Maurel S, Stankovic Stojanovic K, Avellino V, Girshovich A, Letavernier E, Grateau G, Baud L, Girot R, Lionnet F, Haymann JP: Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease. Clin J Am Soc Nephrol 9: 648–653, 2014 24458070
Goossens JP, Statius van Eps LW, Schouten H, Giterson AL: Incomplete renal tubular acidosis in sickle cell disease. Clin Chim Acta 41: 149–156, 1972 4645229
DeFronzo RA, Taufield PA, Black H, McPhedran P, Cooke CR: Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med 90: 310–316, 1979 34341
Ho PK, Alleyne GA: Defect in urinary acidification in adults with sickle-cell anaemia. Lancet 2: 954–955, 1968 4176270
Silva Junior GB, Vieira AP, Couto Bem AX, Alves MP, Meneses GC, Martins AM, Sanches TR, Andrade LC, Seguro AC, Libório AB, Daher EF: Renal tubular dysfunction in sickle cell disease. Kidney Blood Press Res 38: 1–10, 2013 24504378
Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA: Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 72: 188–192, 1982 7036725
Deutschmann HA, Weger M, Weger W, Kotanko P, Deutschmann MJ, Skrabal F: Search for occult secondary osteoporosis: Impact of identified possible risk factors on bone mineral density. J Intern Med 252: 389–397, 2002 12528756
Vallet M, Metzger M, Haymann JP, Flamant M, Gauci C, Thervet E, Boffa JJ, Vrtovsnik F, Froissart M, Stengel B, Houillier P; NephroTest Cohort Study group: Urinary ammonia and long-term outcomes in chronic kidney disease. Kidney Int 88: 137–145, 2015 25760321
Chatel B, Messonnier LA, Bendahan D: Do we have to consider acidosis induced by exercise as deleterious in sickle cell disease? Exp Physiol 103: 1213–1220, 2018 30024072
Walsh SB, Shirley DG, Wrong OM, Unwin RJ: Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: An alternative to ammonium chloride. Kidney Int 71: 1310–1316, 2007 17410104
Arlet JB, Ribeil JA, Chatellier G, Eladari D, De Seigneux S, Souberbielle JC, Friedlander G, de Montalembert M, Pouchot J, Prié D, Courbebaisse M: Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: A prospective observational cohort study. BMC Nephrol 13: 83, 2012 22866669
Bartolucci P, Brugnara C, Teixeira-Pinto A, Pissard S, Moradkhani K, Jouault H, Galacteros F: Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood 120: 3136–3141, 2012 22919030
Di Liberto G, Kiger L, Marden MC, Boyer L, Poitrine FC, Conti M, Rakotoson MG, Habibi A, Khorgami S, Vingert B, Maitre B, Galacteros F, Pirenne F, Bartolucci P: Dense red blood cell and oxygen desaturation in sickle-cell disease. Am J Hematol 91: 1008–1013, 2016 27380930
Yoshino M, Amerian R, Brautbar N: Hyporeninemic hypoaldosteronism in sickle cell disease. Nephron 31: 242–244, 1982 6750423
Kato GJ, Gladwin MT, Steinberg MH: Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21: 37–47, 2007 17084951
Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP: Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 886–895, 2004 14985486
Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaïci A, Hajji L, O’Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G: A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 365: 44–53, 2011 21732836
Bartolucci P, Habibi A, Stehlé T, Di Liberto G, Rakotoson MG, Gellen-Dautremer J, Loric S, Moutereau S, Sahali D, Wagner-Ballon O, Remy P, Lang P, Grimbert P, Audureau E, Godeau B, Galacteros F, Audard V: Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease. J Am Soc Nephrol 27: 1847–1853, 2016 26586692
Olaniran KO, Eneanya ND, Nigwekar SU, Vela-Parada XF, Achebe MM, Sharma A, Thadhani RI: Sickle cell nephropathy in the pediatric population. Blood Purif 47: 205–213, 2019 30517931
Ricós C, Alvarez V, Cava F, García-Lario JV, Hernández A, Jiménez CV, Minchinela J, Perich C, Simón M: Current databases on biological variation: Pros, cons and progress. Scand J Clin Lab Invest 59: 491–500, 1999 10667686
Kraut JA, Madias NE: Re-evaluation of the normal range of serum total CO 2 concentration. Clin J Am Soc Nephrol 13: 343–347, 2018 29339355
Dhayat NA, Gradwell MW, Pathare G, Anderegg M, Schneider L, Luethi D, Mattmann C, Moe OW, Vogt B, Fuster DG: Furosemide/fludrocortisone test and clinical parameters to diagnose incomplete distal renal tubular acidosis in kidney stone formers. Clin J Am Soc Nephrol 12: 1507–1517, 2017 28775126
Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, Young BA, Lettre G, Peralta CA, Katz R, Hyacinth HI, Quarells RC, Grove ML, Bick AG, Fontanillas P, Rich SS, Smith JD, Boerwinkle E, Rosamond WD, Ito K, Lanzkron S, Coresh J, Correa A, Sarto GE, Key NS, Jacobs DR, Kathiresan S, Bibbins-Domingo K, Kshirsagar AV, Wilson JG, Reiner AP: Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 312: 2115–2125, 2014 25393378
Derebail VK, Ciccone EJ, Zhou Q, Kilgore RR, Cai J, Ataga KI: Progressive decline in estimated GFR in patients with sickle cell disease: An observational cohort study. Am J Kidney Dis 74: 47–55, 2019 30797615

Auteurs

Maud Cazenave (M)

Nephrology and Renal Transplantation Department, Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France.

Vincent Audard (V)

Nephrology and Renal Transplantation Department, Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Henri Mondor Hospital, AP-HP, Paris Est Créteil University, Créteil, France.

Jean-Philippe Bertocchio (JP)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, INSERM U1138, Centre National de la Recherche Scientifique (CNRS) ERL8228, Paris, France.

Anoosha Habibi (A)

Sickle Cell Referral Center, Internal Medicine Unit, IMRB team 2, UPEC, Labex GRex, Henri Mondor Hospital, AP-HP, Créteil, France.

Stéphanie Baron (S)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, INSERM U1138, Centre National de la Recherche Scientifique (CNRS) ERL8228, Paris, France.

Caroline Prot-Bertoye (C)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, INSERM U1138, Centre National de la Recherche Scientifique (CNRS) ERL8228, Paris, France.

Jugurtha Berkenou (J)

Sickle Cell Referral Center, Internal Medicine Unit, IMRB team 2, UPEC, Labex GRex, Henri Mondor Hospital, AP-HP, Créteil, France.

Gérard Maruani (G)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, Necker-Enfants Malades Institute, INSERM U1151-CNRS UMR8253, Paris, France; and.

Thomas Stehlé (T)

Nephrology and Renal Transplantation Department, Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Henri Mondor Hospital, AP-HP, Paris Est Créteil University, Créteil, France.

Nicolas Cornière (N)

Nephrology Department, Felix Guyon Hospital, Saint-Denis, Réunion Island, France.

Hamza Ayari (H)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, INSERM U1138, Centre National de la Recherche Scientifique (CNRS) ERL8228, Paris, France.

Gérard Friedlander (G)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, Necker-Enfants Malades Institute, INSERM U1151-CNRS UMR8253, Paris, France; and.

Frédéric Galacteros (F)

Sickle Cell Referral Center, Internal Medicine Unit, IMRB team 2, UPEC, Labex GRex, Henri Mondor Hospital, AP-HP, Créteil, France.

Pascal Houillier (P)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, INSERM U1138, Centre National de la Recherche Scientifique (CNRS) ERL8228, Paris, France.

Pablo Bartolucci (P)

Sickle Cell Referral Center, Internal Medicine Unit, IMRB team 2, UPEC, Labex GRex, Henri Mondor Hospital, AP-HP, Créteil, France.

Marie Courbebaisse (M)

Physiology Department, European Georges Pompidou University Hospital, AP-HP, Paris Descartes University, Necker-Enfants Malades Institute, INSERM U1151-CNRS UMR8253, Paris, France; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH